These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics. Baker KR; Jana B; Hansen AM; Nielsen HM; Franzyk H; Guardabassi L Front Cell Infect Microbiol; 2019; 9():236. PubMed ID: 31334131 [TBL] [Abstract][Full Text] [Related]
3. Repurposing azithromycin and rifampicin against Gram-negative pathogens by combination with peptide potentiators. Baker KR; Jana B; Hansen AM; Vissing KJ; Nielsen HM; Franzyk H; Guardabassi L Int J Antimicrob Agents; 2019 Jun; 53(6):868-872. PubMed ID: 30447380 [TBL] [Abstract][Full Text] [Related]
4. Dilipid Ultrashort Tetrabasic Peptidomimetics Potentiate Novobiocin and Rifampicin Against Multidrug-Resistant Gram-Negative Bacteria. Ramirez D; Berry L; Domalaon R; Brizuela M; Schweizer F ACS Infect Dis; 2020 Jun; 6(6):1413-1426. PubMed ID: 32357292 [TBL] [Abstract][Full Text] [Related]
5. Re-sensitization of Multidrug-Resistant and Colistin-Resistant Gram-Negative Bacteria to Colistin by Povarov/Doebner-Derived Compounds. Onyedibe KI; Nemeth AM; Dayal N; Smith RD; Lamptey J; Ernst RK; Melander RJ; Melander C; Sintim HO ACS Infect Dis; 2023 Feb; 9(2):283-295. PubMed ID: 36651182 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Corbett D; Wise A; Langley T; Skinner K; Trimby E; Birchall S; Dorali A; Sandiford S; Williams J; Warn P; Vaara M; Lister T Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533232 [TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
8. Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria. Yu Y; Zhao H; Lin J; Li Z; Tian G; Yang YY; Yuan P; Ding X Int J Antimicrob Agents; 2022 May; 59(5):106582. PubMed ID: 35378227 [TBL] [Abstract][Full Text] [Related]
9. Bicyclomycin Activity against Multidrug-Resistant Gram-Negative Pathogens. Wang W; Zhu X; Luo H; Wang Z; Hong A; Zeng J; Li L; Wang D; Deng X; Zhao X Microbiol Spectr; 2023 Feb; 11(1):e0379022. PubMed ID: 36533939 [TBL] [Abstract][Full Text] [Related]
11. Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli. Domalaon R; Okunnu O; Zhanel GG; Schweizer F J Antibiot (Tokyo); 2019 Aug; 72(8):605-616. PubMed ID: 31028351 [TBL] [Abstract][Full Text] [Related]
12. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria. Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989 [TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Hu YF; Liu CP; Wang NY; Shih SC BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962 [TBL] [Abstract][Full Text] [Related]
15. Ebselen bearing polar functionality: Identification of potent antibacterial agents against multidrug-resistant Gram-negative bacteria. Chen C; Yang K Bioorg Chem; 2019 Dec; 93():103286. PubMed ID: 31585265 [TBL] [Abstract][Full Text] [Related]
16. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. Personne Y; Curtis MA; Wareham DW; Waite RD J Antimicrob Chemother; 2014 Dec; 69(12):3236-43. PubMed ID: 25134721 [TBL] [Abstract][Full Text] [Related]
17. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481 [TBL] [Abstract][Full Text] [Related]
18. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens. Song M; Liu Y; Huang X; Ding S; Wang Y; Shen J; Zhu K Nat Microbiol; 2020 Aug; 5(8):1040-1050. PubMed ID: 32424338 [TBL] [Abstract][Full Text] [Related]